Bexson Biomedical Inc.

Private Company

Company Logo

Company Overview

Bexson Biomedical Inc. is developing a unique formulation of ketamine for chronic and acute pain disorders. The company's lead project is a novel ketamine delivery system that includes a proprietary formulation of ketamine delivered by a minimally invasive, wearable, subcutaneous infusion pump.

In February 2019, the company was granted Orphan Status for ketamine in the treatment of Complex Regional Pain Syndrome—its lead indication. In parallel, the company is targeting post operative pain management and other large market indications.

Management Team

Gregg Peterson
Chief Executive Officer

Jeffrey Becker, MD
Chief Science Officer

Mark Wiederhold, MD, Ph.D.
VP of Research & Development

Jason Wallach, Ph.D.
Director Bexon Discovery

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile